INTRODUCTION
The T cell growth factor interleukin-2 (IL-2)1 is an antigen-nonspecific, soluble factor produced by T lymphocytes upon activation (1, 2) . In turn, activated T lymphocytes are themselves the responding cells to IL- 2 and become responsive to it after they enter the GC phase of the cell cycle (3) . Recent studies indicate that IL-2 is important in supporting the immunoregulatory functions of T lymphocytes (4) .
Systemic lupus erythematosus (SLE) is a complex autoimmune disease that may result from defective functions of the immunoregulatory T cell circuits (5) . The production of and response to IL-2 have not been previously studied in cells from SLE patients, but in recent communications both have been found diminReceived for publication 5 January 1982 and in revised form 17 March 1982. 1 Abbreviations used in this paper: AMLR, autologous mixed lymphocyte reaction; FCS, fetal calf serum; IL-2, interleukin-2; MEM, Minimum Essential Medium; MNC, mononuclear cells; PHA, phytohemagglutinin; SLE, systemic lupus erythematosus.
ished in NZB/NZW F, and MRL/lpr mice, animal models of SLE (6, 7) .
We report here evidence of a decreased production of and response to IL-2 by activated T lymphocytes from patients with SLE as compared with those from normal subjects. This decrease was more marked in patients with active than in those with inactive disease. Our findings may contribute to the characterization of the immunoregulatory aberration that causes and/ or perpetuates SLE.
METHODS
Subjects. We studied 19 SLE patients who fulfilled at least four of the preliminary criteria for classification of this disease (8) . All but one were females. Their age ranged from 25 to 58 yr (mean, 30.2). No patient was receiving corticosteroids, antimalarial, or immunosuppressive drugs nor had received them for at least 3 mo. Nonsteroidal antiinflammatory agents were stopped at least a week before the time of the study in a few patients who were taking them.
Patients fell into two distinct categories in regard to disease activity. Eight had active disease requiring treatment and were studied before its initiation. The other 11 have been in remission from 1 to 8 yr and have had all medication withdrawn. When their disease was active they all had amply fulfilled the aforementioned classification criteria.
We studied as controls 12 healthy volunteers whose ages ranged from 23 to 35 yr with a mean of 28.1. Six were female.
Cells' separation and purification. Peripheral venous blood drawn into heparinized syringes (10 IU/ml) was diluted in an equal volume of phosphate-buffered saline pH 7.4 and centrifuged on Ficoll-Hypaque cushions of a 1.077 g/ml density.
Mononuclear cells (MNC) were recovered at the interface and washed twice in Minimum Essential Medium (MEM). T and non-T cells were purified from MNC by rosetting with sheep erythrocytes. For this, we mixed 107 MNC in 1 ml of MEM with 2 ml of a 2% suspension of sheep erythrocytes and 0.5 ml of gamma globulin-free fetal calf serum (FCS) (Gibco Laboratories Grand Island Biologicals Co., Grand Island, NY). The mixture was centrifuged 10 
RESULTS
Production of IL-2 activity by lymphocytes from patients or controls. As shown in Fig. 1 , T cells from SLE patients produced significantly less IL-2 activity in comparison with those from normal subjects (P < 0.0001 at all four dilutions of supernatant), as reflected by the [3H]thymidine incorporation of normal activated T cells exposed to their supernatants. Findings were similar to those shown in Fig. 1 T cells from SLE patients with active disease produced significantly less IL-2 than those from patients with inactive disease (P < 0.005 at all four dilutions). Decreased production of IL-2 by T cells from SLE patients occurred with cells activated with PHA as well as with cells activated in AMLR (Fig. 1, a and b) .
All SLE patients with active disease and all but one with inactive disease had PHA-stimulated T cells that produced less IL-2 activity than the mean -2 SD of that produced by cells from normal subjects. Only one patient with inactive disease had a production of IL-2 activity by her T cells upon stimulation in AMLR similar to that of normal but she was not the same patient who had a normal IL-2 production upon PHA activation. Therefore, no patient's cells yielded normal levels of IL-2 activity with both stimuli.
To rule out the possibility that an antibody produced by SLE cells in culture might be present in their supernatants and could therefore interfere with the IL-2 activity, the supernatants of PHA-stimulated cells from three SLE The differences between normal activated T cells and those from SLE patients, both active and inactive, were significant at the P <0.0001 level except in the 1:20 dilution with PHA activation (P < 0.0005). The differences between cells from patients with active and those of patients with inactive disease were significant at the P < 0.001 level in all instances except in the 1:20 dilution with AMLR activation (P < 0.005), as determined by t tests.
( Table I) . T lymphocytes from patients with active disease responded less to IL-2 than those from patients with inactive disease. These differences were noticeable with all dilutions of normal IL-2. Response of T cells from SLE patients to their own IL-2 activity was decreased proportionately to their diminished response and to the lower amounts of this factor found in their supernatants (data not shown). None of the SLE patients, whether active or inactive, showed T cell responses to IL-2 activity within the mean -SD of the normal subjects. Somewhat higher response to IL-2 by nonstimulated T cells from SLE patients than by those from normal controls was noticed (Table I) .
Absorption of IL-2 by T lymphocytes from SLE patients or controls. Fig. 2 (10) and corticosteroids (11) may affect IL-2 production we selected our controls to be of a similar age group as that of our patients, and our patients to be devoid of any treatment when studied. The finding of decreased production of and response to IL-2 by T cells from SLE patients is not surprising. IL-2 is known to support T cell proliferation under mitogenic (12) or antigenic stimuli (13) as well as their response in AMLR (14) . It also contributes to the generation of natural cytotoxicity (4) , to the abrogation of the suppressor cell function induced by concanavalin-A (15), and to the promotion of helper cell function (4, 16) . It may contribute to the postthymic maturation of T cells (17) . All of these functions have been found altered in SLE (5, (18) (19) (20) (21) (22) (23) . Furthermore, NZB/ NZW F1 hybrids and MRL/lpr mice, animal models of SLE, have been recently shown to have a similar defect in the response to and production of IL-2 (6, 7).
The culture conditions in our assays rules out the possibility that serum factors prevented the interaction of IL-2 with surface receptors on cells from SLE patients. Indeed, unstimulated T cells from SLE patients seemed to respond the same or better to IL-2 activity * than those of normal subjects.
The abnormalities of T cell function found in SLE have been ascribed to lymphocytotoxic (24) or anti-TIVE nuclear antibodies (25) causing deletion of T cell sub--populations. Specific decrease of Ty cells (26) , autologous rosette forming T cells (5) , and OKT 5-8 positive ls from cells (27) 
